Agenda

Thursday, October 23, 2025

8:15 am - 9:00 am

Registration and Breakfast

9:00 am - 9:10 am

Welcome Remarks

Randolph Escobar-Behan | Senior Scientist, Medicinal Chemistry, AstraZeneca

9:10 am - 10:30 am

Graduate Student/Postdoc Talks (4 x 20 min)

A Chemical Mechanistic Path Leads the Way to Cellular Argpyrimidine

Dr. Tin Pham | Scheck Group, Tufts University

Insight into FtmOx1 through substrate analogs

Brandon Singh | Ting Group, Brandeis University

Identification and structural optimization of 2-amido-pyrazines as novel P. falciparum inhibitors

Dr. Alicia Wagner | Manetsch Group, Northeastern University

Antibody-Bottlebrush Conjugated Degraders (ABCDs) – novel constructs for targeted protein degradation therapy

Aiden Wang | Johnson Group, Massachusetts Institute of Technology

10:30 am - 11:15 am

Coffee Break and Poster Session #1

11:15 am - 12:15 pm

Academic Keynote

Rewriting protein modifications

12:15 pm - 1:30 pm

Networking Lunch

1:30 pm - 2:30 pm

Graduate Student/Postdoc Talks (3 x 20 min)

Electrochemical Azolation of Electron-rich Fluoroarenes: A Controlled Redox Chain Unlocks C–N Bond-forming e-SNAr

Dr. Brett Akana-Schneider | Derosa Group, Boston University

Building Robust Automated Workflows for Reaction Optimization and Multi-Parallel Synthesis at AstraZeneca

Richard S. Morales | Scientist, Automated Chemical Synthesis, AstraZeneca

Catalytic Prenyl Conjugate Additions for Synthesis of Enantiomerically Enriched PPAPs

Shawn Ng | Hoveyda Group, Boston College

2:30 pm - 3:15 pm

Coffee Break and Poster Session #2

3:15 pm - 3:55 pm

Graduate Student/Postdoc Talks (2 x 20 min)

Catalytic Asymmetric Synthesis of Quaternary Ammonium Ions

Dr. Sepand Nistanaki | Jacobsen Group, Harvard University

Total Synthesis of (+)-Hazuntiphylline, (–)-Anhydrohazuntiphyllidine, and (–)-Hazuntiphyllidine

Robert-Cristian Raclea | Movassaghi Group, Massachusetts Institute of Technology

3:55 pm - 4:55 pm

Industrial Keynote

Discovery of Selective PARP1 Inhibitors: saruparib (AZD5305) and AZD9574

Dr. Jeffrey Johannes | Director, Medicinal Chemistry, AstraZeneca

4:55 pm - 5:00 pm

Closing Remarks

5:00 pm - 6:30 pm

Networking Reception